NDAC weighty decision: pediatric dosing schedule should be weight-based.

PEDIATRIC WEIGHT-BASED DOSING SCHEDULE FOR SYSTEMIC PRODUCTS PREFERRED by FDA's Nonprescription Drugs Advisory Committee, the group agreed at a Jan. 13 meeting. In response to an FDA question seeking the committee's consensus on the preferred basis for determining OTC systemic dosages and labeling for children under 12 years of age, NDAC Chair Randy Juhl, PhD, University of Pittsburgh, noted the general conclusion was that "weight would be our first choice and age would be our second choice."